stockrow
Friday 6 November 2026
Export HYPR’s income statement to Excel — free account
Hyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024.
- Revenue
- +44.8%
- EPS
- +25.0%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
0.71
0.02
+2.90%
Follow HYPR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 7 | 11 | 13 | 14 | 17 | +115.2% | 21 | 27 | 38 | +41.5% | |
| Gross margin, % | — | — | — | — | (162.24) | (78.01) | 13.31 | 43.12 | 45.70 | 49.79 | 51.41 | +212.0 pt | ||||||
| EBT | — | — | — | — | (23) | (65) | (73) | (44) | (41) | (36) | (35) | +8.7% | ||||||
| EBT margin, % | — | — | — | — | (7,968.37) | (4,334.96) | (1,073.73) | (401.00) | (315.90) | (262.29) | (210.75) | +7,706.1 pt | ||||||
| Net income | — | 0 | — | — | (23) | (65) | (73) | (44) | (41) | (36) | (35) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.19 | 0.41 | 0.10 | 0.15 | 0.18 | 0.17 | 0.17 | (3.0%) | |||||
| Earnings | — | — | — | — | (15.38) | (17.57) | (1.04) | (0.62) | (0.56) | (0.43) | (0.38) | (51.1%) | ||||||
| Cash flow | — | — | — | — | (14.13) | (12.78) | (1.03) | (0.59) | (0.54) | (0.34) | (0.27) | (52.5%) | ||||||
| Capex | — | — | — | — | (1.03) | (0.73) | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | (57.4%) | ||||||
| Free cash flow | — | — | — | — | (15.16) | (13.52) | (1.04) | (0.60) | (0.54) | (0.36) | (0.28) | (52.8%) | ||||||
| Book value | — | — | — | — | (40.09) | 50.45 | 1.76 | 1.18 | 0.68 | 0.50 | 0.37 | n/m | ||||||
| Shares, m | — | — | — | — | 2 | 4 | 70 | 71 | 72 | 82 | 90 | +121.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 17.89 | 8.58 | 7.30 | 4.94 | 5.91 | 4.16 | 7.4 | ||||||
| P/B | — | — | — | — | 12,612.60 | 0.14 | 0.47 | 0.95 | 1.30 | 1.95 | 1.87 | 2,102.9 | ||||||
| EV/Sales | — | — | — | — | 0.00 | (109.89) | (8.77) | 0.43 | 2.02 | 3.25 | 2.26 | (18.8) | ||||||
| EV/FCF | — | — | — | — | 0.00 | 3.30 | 0.82 | (0.11) | (0.67) | (1.51) | (1.36) | 0.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (22) | (47) | (72) | (42) | (39) | (28) | (27) | +5.4% | |||||
| Capex | — | — | — | — | (2) | (3) | (1) | (1) | 0 | (1) | 0 | (5.4%) | ||||||
| Free cash flow | — | — | — | — | (23) | (50) | (73) | (43) | (39) | (29) | (28) | +4.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 64 | 182 | 120 | 80 | 45 | 39 | 50 | (9.4%) | |||||
| Net debt | — | — | — | — | (64) | (191) | (118) | (76) | (38) | (36) | (32) | (10.9%) | ||||||
| Shareholders’ equity | — | — | — | — | (61) | 186 | 124 | 84 | 49 | 41 | 37 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (65.51) | (47.34) | (43.48) | (38.76) | (53.19) | (62.32) | (64.40) | +3.2 pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (842.69) | (349.88) | (237.66) | (467.02) | (401.79) | (467.0) pt | ||||||
| ROE | — | — | — | — | (37.43) | (103.62) | (47.21) | (42.51) | (61.03) | (79.01) | (96.97) | (41.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 193 | 136 | 131 | 111 | 102 | — | +119.5% | |||||
| Revenue/emp, $m | — | — | — | — | 0.15 | 0.01 | 0.05 | 0.08 | 0.12 | 0.13 | — | (2.0%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Hyperfine, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZOMDF Zomedica Corp. | $95.4M | — (loss-making) | — (loss-making) | +22.29% (above 0%: growing) | n/m | +32.51% (above 0%: growing) | 61.06% | (34.60%) | Compare |
| NYXH Nyxoah SA | $82.6M | — (loss-making) | — (loss-making) | +486.62% (above 0%: growing) | n/m | +4.01% (above 0%: growing) | 59.73% | (268.25%) | Compare |
| SERA Sera Prognostics, Inc. | $82.1M | — (loss-making) | — (loss-making) | +162.50% (above 0%: growing) | n/m | −12.79% (below 0%: shrinking) | 0.00% | (21,159.52%) | Compare |
| ECOR electroCore, Inc. | $79.3M | — (loss-making) | — (loss-making) | +11.52% (above 0%: growing) | n/m | −69.10% (below 0%: shrinking) | 88.47% | (16.06%) | Compare |
| LUCD Lucid Diagnostics Inc. | $79.3M | — (loss-making) | — (loss-making) | +26.74% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 1.97% | (868.45%) | Compare |
| OM Outset Medical, Inc. | $77.0M | — (loss-making) | — (loss-making) | +14.15% (above 0%: growing) | n/m | −61.85% (below 0%: shrinking) | 40.69% | (36.52%) | Compare |
| HYPR Hyperfine, Inc. | $72.7M | — (loss-making) | — (loss-making) | +44.81% (above 0%: growing) | n/m | +13.43% (above 0%: growing) | 50.72% | (216.93%) | |
| MBOT Microbot Medical Inc. | $71.9M | — (loss-making) | — | +1,047.62% (above 0%: growing) | n/m | −98.72% (below 0%: shrinking) | (266.80%) | (2,567.63%) | Compare |
| LNSR LENSAR, Inc. | $67.6M | 3.9× | 6.9× | +18.37% (above 0%: growing) | n/m | +96.81% (above 0%: growing) | 59.27% | 12.94% | Compare |
| Median of peers | $79.3M | — | — | +24.52% | — | −9.92% | 49.98% | (152.39%) |
Pay and ownership Proxy statement filed 8 April 2026
Ownership
Directors and executive officers, together
79.40% of the votes
Jonathan M. Rothberg, Ph.D.
78.90% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement